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Intranasal Dexmedetomidine for
Procedural Distress in Children: A
Systematic Review
Naveen Poonai, MD,a,b,c Joseph Spohn, MSc,b Ben Vandermeer, MSc,d Samina Ali, MDCM,e,f Maala Bhatt, MD,g
Shawn Hendrikx, MLIS,a Evelyne D. Trottier, MDCM,h Vikram Sabhaney, MD,i Amit Shah, MD,b Gary Joubert, MD,a,b
Lisa Hartling, PhDd

CONTEXT:

Intranasal dexmedetomidine (IND) is an emerging agent for procedural distress in children.

OBJECTIVE:

abstract

To explore the effectiveness of IND for procedural distress in children.

DATA SOURCES: We performed electronic searches of Medline (1946–2019), Embase (1980–2019), Google
Scholar (2019), Cumulative Index to Nursing and Allied Health Literature (1981–2019), and Cochrane
Central Register.
STUDY SELECTION:

We included randomized trials of IND for procedures in children.

DATA EXTRACTION: Methodologic

quality of evidence was evaluated by using the Cochrane Collaboration’s risk
of bias tool and the Grading of Recommendations Assessment, Development, and Evaluation system,
respectively. The primary outcome was the proportion of participants with adequate sedation.

RESULTS: Among 19 trials (N = 2137), IND was superior to oral chloral hydrate (3 trials), oral midazolam (1
trial), intranasal midazolam (1 trial), and oral dexmedetomidine (1 trial). IND was equivalent to oral chloral
hydrate (2 trials), intranasal midazolam (2 trials), and intranasal ketamine (3 trials). IND was inferior to oral
ketamine and a combination of IND plus oral ketamine (1 trial). Higher doses of IND were superior to lower
doses (4 trials). Adverse effects were reported in 67 of 727 (9.2%) participants in the IND versus 98 of 591
(16.6%) in the comparator group. There were no reports of adverse events requiring resuscitative
measures.
LIMITATIONS:

The adequacy of sedation was subjective, which possibly led to biased outcome reporting.

CONCLUSIONS: Given the methodologic limitations of included trials, IND is likely more effective at sedating
children compared to oral chloral hydrate and oral midazolam. However, this must be weighed against
the potential for adverse cardiovascular effects.
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WHAT’S KNOWN ON THIS SUBJECT: Painful and
distressing procedures are commonly performed in children.
Oral and intranasal midazolam, the most commonly used
anxiolytics, have limited evidence of beneﬁt. Intranasal
dexmedetomidine is a relatively new agent, but its study has
been limited by small sample sizes.
WHAT THIS STUDY ADDS: Intranasal dexmedetomidine
may provide more effective sedation than chloral hydrate or
midazolam. Limited data exist for minor, painful procedures
such as laceration repair or lumbar puncture. The beneﬁts of
administration must be weighed against the potential for
adverse cardiovascular effects.
To cite: Poonai N, Spohn J, Vandermeer B, et al. Intranasal
Dexmedetomidine for Procedural Distress in Children: A
Systematic Review. Pediatrics. 2020;145(1):e20191623
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In the hospital, painful and
distressing procedures including
laceration repair, lumbar puncture,1
intravenous (IV) insertion,2–6 and
venipuncture6,7 are common.
However, administration of analgesia
is inconsistent for painful procedures,
and procedural distress is poorly
managed.2–6 In a Canadian survey of
.3000 hospitalized children,
researchers found that the children
received .6 painful procedures per
day, and less than one-third of them
received analgesia.8 Such procedures
result not only in the reported pain
but also in closely linked procedural
distress, which often requires
a different approach than analgesia.
In addition, other nonpainful
diagnostic procedures, such as
computed tomography (CT) and MRI,
require a child to lie motionless,
which can be anxiety provoking
across the age spectrum, and often
require some level of sedation for
younger patients.
To address these issues of sedation
and anxiolysis, intranasal therapies
for procedural distress can be
noninvasively administered9 and
require less procedural skill than IV
insertion.10 Currently, midazolam is
the most commonly used anxiolytic in
children because of its rapid onset of
action and amnestic properties.11
However, when used via the
intranasal route, it has an unpleasant
taste, can be irritating to the nasal
mucosa,12,13 and has adverse
effects,11,14 underscoring the need for
appropriate monitoring. Furthermore,
2 Cochrane reviews have differing
conclusions regarding midazolam’s
effectiveness for children’s
procedures,11,14 suggesting that
additional evidence for alternative
agents is needed.
Dexmedetomidine is a central a2adrenergic receptor agonist with
analgesic and anxiolytic properties,
and its use outside the intensive care
and preanesthetic setting is gaining
popularity.15 Authors of 3 systematic
reviews suggest dexmedetomidine is

effective for procedural distress in
children.15–17 However, they mainly
reported effects by IV route, and only
1 explored intranasal
dexmedetomidine (IND), focusing on
anesthetic premedication.16 To date,
no large trial or review exists to guide
the use of IND for procedural distress
in children. With the emerging
popularity of dexmedetomidine for
procedural distress and a desire for
less invasive approaches in children,
a comprehensive review of IND is
needed to guide its use. We sought to
summarize the effectiveness of IND
for children undergoing painful and
distressing procedures.

METHODS
This review followed the Preferred
Reporting Items for Systematic
Reviews and Meta-Analysis
guidelines.18

Eligibility Criteria
We included all published and
unpublished randomized trials
comparing IND as monotherapy to
any comparator for a procedure in
children ,19 years and reported
adequacy of sedation. Trials of both
adults and children were included if
the authors provided pediatricspeciﬁc data. We excluded substudies,
crossover studies, abstracts with
insufﬁcient information, and studies
of anesthetic premedication unless
they involved a painful procedure.
The primary outcome was the
proportion of participants deemed to
be adequately sedated on the basis of
the investigators’ opinion. Clinically,
we believed this to be the most
pragmatic, relevant, and feasible
approach to describing relief of
procedural distress. Methodologically,
we believed this to be a consistent
way of overcoming differences in
sedation scales. Secondary outcomes
included the need for additional
sedation, onset and duration of
sedation, length of stay, analgesia,
adverse events, and acceptance of
intranasal administration.

Data Sources
A medical librarian (S.H.) developed
the search strategy. We performed
electronic searches of Medline
(1946–2018), Embase (1980–2018),
Scopus (2018), Web of Science
(2018), Google Scholar (2018),
Cochrane Central Register (2018),
and Cumulative Index to Nursing and
Allied Health Literature (1981–2018).
The search was completed in January
2018 and repeated in February and
July 2019 without language
restriction (Supplemental Tables 2
through 5). Our gray literature search
was informed by the Canadian
Agency for Drugs and Technologies in
Health checklist.19 We checked
reference lists of included trials and
systematic reviews. We contacted
corresponding authors when data on
the primary outcome were missing.

Study Selection and Data Extraction
Two authors (N.P., J.S.) independently
screened titles, abstracts, and full
texts for inclusion. Disagreements
were resolved through discussion.
The primary author entered the data
into Review Manager version 5.2.11
and GRADEpro Guideline
Development Tool version 3.6.

Risk of Bias in Individual Studies
Two authors (N.P., J.S.) independently
evaluated methodologic rigor using
the Cochrane Collaboration’s risk of
bias tool20 and outcome-speciﬁc
ratings of the overall quality of
evidence using the Grading of
Recommendations Assessment,
Development, and Evaluation
(GRADE) system.21

Summary Measures and Synthesis of
Results
A priori, we considered meta-analyses
if there was homogeneity in
procedures, dosing regimen, and
outcome measures. However, metaanalyses were not performed on any
outcome because of substantial
heterogeneity. Instead, we conducted
a descriptive analysis of each study’s
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design, population, and primary
outcome. On the basis of the
classiﬁcation system of Tricco et al,22
we categorized the results of
individual studies on the basis of the
outcome of adequate sedation as
unfavorable (effect in favor of the
comparator with P # .05), neutral
(nonstatistically signiﬁcant difference
between interventions with P . .05),
favorable (effect in favor of the
experimental agent [IND] with P #
.05), and indeterminate (unable to
judge because of conﬂicting and
multiple primary outcomes). We used
ranges to describe onset and duration
of sedation and length of stay. We
used proportions to describe
acceptance of intranasal
administration. Agreement between
reviewers was described by using
raw agreement.

Risk of Bias Across Studies
Publication bias was assessed by
using a funnel plot.

Additional Analyses
We evaluated statistical
heterogeneity using the I2 statistic.

RESULTS

trials),39 and dental work (2
trials).40,41 All trials were published
in English in peer-reviewed journals
and included 2137 children (847 of
2093; 40.5% girls) who were age
1 month to 14 years. Demographic
statistics excluded Patel et al41
because these details were not
speciﬁed. IND was compared to oral
dexmedetomidine,41 chloral
hydrate,23,26,28,30,33 IND plus oral
ketamine,37 intranasal or oral
midazolam,31,34,39,40 and intranasal or
oral ketamine.35–37,40 In 6 trials, the
authors compared different doses of
IND24,25,29,32 or methods of IND
administration27,38 (Table 1).

Risk of Bias Within Studies
Most trials were judged as low risk of
bias for random sequence generation,
blinding, incomplete outcome data,
and selective reporting (Fig 2). For
allocation concealment, most trials
were judged as unclear risk of bias. Li
et al29 was judged as high risk of bias
for incomplete outcome data because
14 of 67 participants receiving
1 mg/kg of IND withdrew
postrandomization with no outcome
data reported. Surendar et al40
reported vital signs instead of

adverse effects and was judged as
unclear risk of bias.

Risk of Bias Across Studies
The overall quality of evidence based
on the GRADE system was judged as
high (length of stay), moderate (need
for additional sedation, duration of
sedation, and adverse effects), or low
(adequacy of sedation, onset of
sedation, and analgesia) (Fig 3).

Adequacy of Sedation
Adequacy of sedation was reported in
18 of 19 trials. A validated sedation
instrument was used in 10
trials25–27,29–34,36 and included the
Observer’s Assessment of Alertness/
Sedation Scale, Modiﬁed Observer’s
Assessment of Alertness/Sedation
Scale, Ramsay Sedation Scale, and the
University of Michigan Sedation Scale
(Table 1). In 7 trials, the authors used
nonvalidated scales to measure
sedation.24,28,35–37,40,41 In 2 trials, the
authors did not report adequacy of
sedation but pain during IV insertion
using the Faces, Legs, Activity, Cry,
and Consolability (FLACC) scale38 and
anxiety during early stages of
laceration repair using the Yale
Preoperative Anxiety Scale.39 The
proportion of participants with

Study Selection
Nineteen trials (N = 2137) were
included. Thirteen involved IND
versus a non-IND comparator. Six
were used to compare different doses
of IND or methods of IND
administration (Fig 1).

Study Characteristics
IND was studied for the following
nonpainful procedures: ophthalmic
examination (3 trials),23–25
transthoracic echocardiography
(TTE) (2 trials),26,27 auditory
brainstem response (ABR) testing (2
trials),28,29 CT (3 trials)29–31 and MRI
(2 trials),32,33 and visually evoked
potentials (VEPs) (1 trial).29 IND was
studied for the following painful
procedures: IV insertion (6
trials),31,34–38 laceration repair (1

FIGURE 1

Study ﬂow diagram of reasons for exclusion include adult population and/or IV dexmedetomidine.
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Measure of Effectiveness of Sedation

Results

Summary

Sedation level based on Groningen
Distress Scale (IV insertion) and
proportion with “adequate sedation”
based on Ramsay Sedation score $4
(CT)

IND 2 mg/kg 28 of 30 (93.3%) versus IND 1 mg/kg 20 of Favorable for IND 2 mg/kg versus
30 (66.7%) (P = .02)
IND 1 mg/kg

IV insertion: signiﬁcantly lower median (IQR) scores Favorable for IND 2.5 mg/kg
with IND 2.5 mg/kg (1 [1]) versus oral midazolam
versus oral midazolam
0.5 mg/kg (2 [1]) (P = .04) Completion of procedure
0.5 mg/kg
not reported CT: IND 2.5 mg/kg 20 of 30 (67%)
versus oral midazolam 0.5 mg/kg 7 of 29 (24%) (P =
.002)
1–8 y (n = 60) IND 1 mg/kg; intranasal
Proportion that allowed IV insertion
IND 1 mg/kg 24 of 30 (80%) versus intranasal
Favorable for IND 1 mg/kg versus
midazolam 0.2 mg/kg
without crying and Observer’s
midazolam 0.2 mg/kg 16 of 30 (53%)
intranasal midazolam
Assessment of Alertness/Sedation score
0.2 mg/kg
#4
1–10 y (n = IND 1 mg/kg; intranasal ketamine Proportion with satisfactory IV cannulation IND 1 mg/kg 20 of 52 (38%) versus intranasal ketamine Neutral for IND 1 mg/kg versus
150)
5 mg/kg; intranasal saline
based on de novo “ease of cannulation
5 mg/kg 18 of 52 (35%) (P = .46) versus intranasal
intranasal ketamine 5 mg/kg
score” $4
saline 1 of 46 (2%) (P , .01 for both agents versus
saline)
4–10 y (n = IND 3 mg/kg; intranasal ketamine IV insertion: proportion with “satisfactory IV insertion: IND 3 mg/kg 27 of 29 (93%) versus
Neutral for IND 3 mg/kg versus
58)
7 mg/kg
acceptance” based on de novo 4-point
intranasal ketamine 7 mg/kg 27 of 29 (93%) (P =
intranasal ketamine 7 mg/kg
scale value $3 MRI: sedation failure
.45)a; MRI: IND 3 mg/kg 4 of 29 (14%) versus
for both IV insertion and MRI
rate based on the Modiﬁed Ramsay
intranasal ketamine 7 mg/kg 6 of 29 (21%) (P = .48);
Sedation Scale
all successfully completed MRI
1 mo–13 y After failure of oral chloral
Adequate sedation based on the Modiﬁed IND 1 mg/kg 56 of 67 (84%) versus IND 1.5 mg/kg 66 of Favorable for higher doses of IND
(n = 213)
hydrate 50 mg/kg: IND 1, 1.5, 2
Observer’s Assessment/Alertness Scale
74 (89%) versus IND 2 mg/kg 51 of 53 (96%) (P =
score from 0 to 3
.03c)
mg/kg

1–6 y (n = 59) IND 2.5 mg/kg; oral midazolam
0.5 mg/kg

5–36 mo (n = After failure of oral or rectal
Proportion with “successful ophthalmic
60)
chloral hydrate 80 mg/kg: IND 1
examination” based on 4-point Likert
mg/kg; IND 2 mg/kg
scale score of 1

IND 2 mg/kg 61 of 71 (85.9%) versus oral chloral
Favorable for IND 2 mg/kg versus
3–36 mo (n = IND 2 mg/kg; oral chloral hydrate Proportion with “successful sedation to
hydrate 45 of 70 (64.3%) (P = .003)
oral chloral hydrate 80 mg/kg
141)
80 mg/kg
complete the examination” based on the
Observer’s Assessment of Alertness/
Sedation score #4
6–24 mo (n = IND 2 mg/kg; IND 3 mg/kg
Modiﬁed Observer’s Assessment of
No signiﬁcant difference in mean (SD) sedation scores Neutral for IND 2 mg/kg vs IND 3
100)
Alertness/Sedation score
between IND 2 mg/kg (2.6 [2.1]) and IND 3 mg/kg
mg/kg
(2.7 [1.9]) (P . .05)

Comparisons

Li et al,29 parallel
group RCT, China,
diagnostic
proceduresb
Li et al,27 parallel
2–36 mo (n = IND 3 mg/kg using either a MAD or “Successful sedation” based on
IND 3 mg/kg via MAD 113 of 137 (83%) versus drops Neutral for IND 3 mg/kg via MAD
group RCT, China,
280)
nasal drops
a University of Michigan Sedation Scale
120 of 142 (85%) (P = .57)
versus drops
TTE
score from 2 to 4
Miller et al,26 parallel 3–36 mo (n = IND 2 mg/kg; IND 3 mg/kg; chloral Adequate sedation based on a Ramsay
IND 2 mg/kg 50 of 50 (100%) versus IND 3 mg/kg (48 of Neutral for IND 2 mg/kg and 3
group RCT, United
150)
hydrate 70 mg/kg
Sedation score $3
50) (96%) versus chloral hydrate 70 mg/kg 48 of 50
mg/kg versus chloral hydrate
70 mg/kg
States and China,
(96%) (P = .36)
TTE

Ibrahim,36 parallel
group RCT, Saudi
Arabia, IV insertion
and MRI

Gyanesh et al,35
parallel group RCT,
India, IV insertion

Gupta et al,34 parallel
group RCT, India, IV
insertion

Cao et al,23 parallel
group RCT, China,
ophthalmic
examination
Chen et al,25 parallel
group RCT, China,
ophthalmic
examination
Gan et al,24 parallel
group RCT, China,
ophthalmic
examination
Ghai et al,31 parallel
group RCT, India, IV
insertion and CT

Source, Trial Design,
Age Range
Country, Indication for
(Analysis
Sedation
Sample Size)

TABLE 1 Characteristics of Included Trials
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Comparisons

Measure of Effectiveness of Sedation

Results

Summary

OR, odds ratio; RCT, randomized controlled trial.
a P value reﬂects between-group differences in overall 4-point scale.
b Includes CT, ABR, and VEPs.
c P value reﬂects overall difference between groups.

“Not anxious” at the time of wound
IND 2 mg/kg 7 of 20 (35%) versus intranasal
Neutral for IND 2 mg/kg versus
Neville et al,39 parallel 1–5 y (n = 38) IND 2 mg/kg; intranasal
group RCT, United
midazolam 0.4 mg/kg
washout based on the Yale Preoperative
midazolam 0.4 mg/kg 1 of 18 (6%) (OR 3; 95% CI
intranasal midazolam
States, laceration
Anxiety Scale score #30
1–12); completion of procedure not reported
0.4 mg/kg
repair
Patel et al,41 parallel 4–9 y (n = 44) IND 2.5 mg/kg; IND 2 mg/kg; oral “Safe and successful” based on a de novo IND 2.5 mg/kg 9 of 11 (82%) versus IND 2 mg/kg 3 of 11 Favorable for IND 2.5 mg/kg
group RCT, India,
dexmedetomidine 4 mg/kg; oral
5-point scale for response to treatment
(27%) versus oral dexmedetomidine 4 mg/kg 0 of 11
versus all other comparators
dental procedures
dexmedetomidine 5 mg/kg
and adequate sedation, physiologic
(0%) versus oral dexmedetomidine 5 mg/kg 0 of 11
parameters, and adverse effects with
(0%) (P = .05c)
a value #2
Qiao et al,37 parallel
2–5 y (n = IND 2.5 mg/kg; oral ketamine
“Successful venous cannulation” based on IND 2.5 mg/kg 20 of 42 (47%) versus oral ketamine
Unfavorable for IND 2.5 mg/kg
135)
6 mg/kg; IND 2 mg/kg plus oral
de novo 5-point sedation scale value #2
6 mg/kg 28 of 41 (68%) versus IND 2 mg/kg plus
group RCT, China, IV
versus combination of IND 2
insertion
ketamine 3 mg/kg
oral ketamine 3 mg/kg 33 of 41 (80%) (P = .006c)
mg/kg plus oral ketamine
3 mg/kg and oral ketamine
6 mg/kg
Reynolds et al,42
6 mo–8 y (n = IND 3 mg/kg; chloral hydrate
“Satisfactory sedation” based on ability of IND 3 mg/kg 39 of 44 (89%) versus chloral hydrate
Favorable for IND 3 mg/kg versus
parallel group RCT,
85)
50 mg/kg
audiologist to complete the procedure
50 mg/kg 27 of 41 (66%) (P = .18)
chloral hydrate 50 mg/kg
United States, ABR
by placing electrodes within 30 min
testing
Surendar et al,40
4–14 y (n = IND 1.5 mg/kg; IND 1 mg/kg;
“Satisfactory sedation” for the ﬁrst 30 min IND 1.5 mg/kg 18 of 21 (86%) versus IND 1 mg/kg 17 of Neutral for IND 1.5 mg/kg and IND
parallel group RCT,
84)
intranasal midazolam
of the procedure based on a de novo 521 (81%) versus intranasal midazolam 0.2 mg/kg 13
1 mg/kg versus intranasal
India, dental
0.2 mg/kg; intranasal ketamine
point scale (4 or 5)
of 21 (62%) versus intranasal ketamine 5 mg/kg 14
midazolam 0.2 mg/kg and
procedures
5 mg/kg
of 21 (67%) (P = .24c)
intranasal ketamine 5 mg/kg
Tug et al,32 parallel
1–10 y (n = IND 3 mg/kg; IND 4 mg/kg
“Adequate sedation” based on Ramsay
IND 3 mg/kg 9 of 30 (30%) versus IND 4 mg/kg 21 of 30 Favorable for IND 4 mg/kg versus
group RCT, Turkey,
60)
Sedation score $5 and no need for
(70%) (P = .002)
IND 3 mg/kg
MRI
rescue sedation for MRI at 45 min
Xie et al,38 parallel
2–5 y (n = IND 2 mg/kg using MAD; IND 2
Response to IV insertion based on FLACC Median (IQR) FLACC score for IND 2 mg/kg using MAD Favorable for IND 2 mg/kg using
group RCT, China, IV
106)
mg/kg using drops
score
was 1 (3.5) versus IND 2 mg/kg using drops was 3
MAD versus IND 2 mg/kg using
insertion
(4) (P = .02); all participants had completed IV
drops
insertions
Yuen et al,30 parallel Age range not IND 3 mg/kg; oral chloral hydrate “Adequate sedation” based on University of IND 3 mg/kg 64 of 87 (74%) versus oral chloral hydrate Neutral for IND 3 mg/kg versus
group RCT, China,
speciﬁed (n =
50 mg/kg
Michigan Sedation Scale score $3
81 of 107 (76%) (P = .74)
oral chloral hydrate 50 mg/kg
CT
196)
Zhang et al,33 parallel 1–6 mo (n = After failure of oral chloral
“Successful sedation” based on the
IND 1 mg/kg 47 of 50 (94%) versus IND 2 mg/kg 49 of Favorable for IND 1 mg/kg and 2
group RCT, China,
150)
hydrate 50 mg/kg: IND 1 mg/kg;
Modiﬁed Observer’s Assessment of
50 (98%) versus oral chloral hydrate 25 mg/kg 40 of
mg/kg versus oral chloral
MRI
IND 2 mg/kg; oral chloral
Alertness/Sedation Scale score #3
50 (80%) (P , .01)
hydrate 25 mg/kg
hydrate 25 mg/kg

Source, Trial Design,
Age Range
Country, Indication for
(Analysis
Sedation
Sample Size)

TABLE 1 Continued

by mucosal atomizer device (MAD) or
nasal drops (113 of 137 [82.5%] vs
120 of 142 [84.5%], respectively; P =
.57]. Xie et al38 found that the median
(interquartile range [IQR]) FLACC
scores were signiﬁcantly better with
2 mg/kg of IND via a MAD versus
nasal drops for IV insertion (1 [0.4] vs
3 [4]; P = .02, respectively]).

Need for Additional Sedation

FIGURE 2
Review authors’ judgements about each risk of bias item presented as percentages across all
included studies.

adequate sedation was 33 of 41
(80.4%) for IND plus oral ketamine,
1086 of 1362 (79.7%) for IND, 241 of
318 (75.7%) for chloral hydrate, 28 of
41 (68.3%) for oral ketamine, 59 of
102 (57.8%) for intranasal ketamine,
30 of 69 (43.4%) for intranasal
midazolam, 7 of 29 (24.1%) for oral
midazolam, and 0 of 22 (0%) for oral
dexmedetomidine. IND was deemed
“favorable” versus chloral hydrate in
3 trials,23,28,33 oral midazolam in 1
trial,31 intranasal midazolam in 1
trial,34 and oral dexmedetomidine in
1 trial.41 IND was deemed “neutral”
versus chloral hydrate in 2 trials,26,30
intranasal midazolam in 2 trials,39,40
and intranasal ketamine in 3
trials.35,36,40 IND was deemed
“unfavorable” versus oral ketamine
and a combination of IND plus oral
ketamine in 1 trial.37

Adequacy of Sedation for Painful and
Nonpainful Procedures
For painful procedures,31,34–41 IND
provided adequate sedation to 145 of
237 (61.2%) vs 151 of 321 (47.1%)
participants among comparators. For
nonpainful procedures,23–33 IND
provided adequate sedation to 862 of
1025 (84.1%) vs 250 of 347 (72.0%)
participants among comparators.
Limiting the comparison of painful
versus nonpainful procedures to
trials using validated instruments,
IND versus comparators provided

adequate sedation to 24 of 30 (80%)
vs 16 of 30 (53.3%) participants
(painful) and 874 of 1021 (85.6%) vs
214 of 277 (77.3%) participants
(nonpainful), respectively.

Differing Doses of IND and Routes of
Nasal Administration
Authors of 6 trials compared different
doses or routes of IND
administration. Gan et al24 found that
2 mg/kg provided adequate sedation
to signiﬁcantly more participants
undergoing ophthalmologic
examination than 1 mg/kg (28 of 30
[93%] vs 20 of 30 [67%],
respectively; P = .02). Chen et al25
found that 2 and 3 mg/kg provided
a similar degree of sedation for
ophthalmologic examination,
successfully sedating 49 of 50 (98%)
and 50 of 50 (100%) participants,
respectively. Tug et al32 found
4 mg/kg of IND provided adequate
sedation to signiﬁcantly more
participants undergoing MRI than
3 mg/kg (20 of 30 [66.7%] vs 7 of 30
[23.3%], respectively; P = .003). Li
et al29 found that higher doses of IND
(1 vs 1.5 vs 2 mg/kg) provided
adequate sedation to increasingly
more participants undergoing CT
scan, ABR testing, or VEPs (56 of 67
[83.6%], 66 of 74 [89.2%], and 51 of
53 [96.2%], respectively; P = .03]. Li
et al27 found no differences in
adequate sedation for 3 mg/kg of IND

Five trials reported on the need for
additional sedation.26,28,31,36,39
Additional sedation was provided to
signiﬁcantly fewer participants in the
IND (22 of 223; 9.9%) versus
comparator groups (47 of 167;
28.1%).

Onset of Sedation
Onset of sedation was reported in 11
trials* and ranged from 7 to
31 minutes for IND and 7 to
44.2 minutes for comparators. Onset
of sedation varied by dose of IND:
1 mg/kg (14.3–19
minutes),24,29,33,34,40 1.5 mg/kg
(18.1–20 minutes),29,40 2 mg/kg
(8.8–25 minutes),23–26,29,33,38,41 2.5
mg/kg (7–20.6 minutes),37,41 3 mg/kg
(13–31 minutes),25–28,30,32,36 and
4 mg/kg (30 minutes).32

Duration of Sedation
Duration of sedation was reported in
6 trials23,25,26,33,36,40 and ranged from
41 to 91.5 minutes for IND and 77 to
85.9 minutes for comparators.

Length of Stay
Length of stay was reported in 4
trials23,24,26,39 and ranged from 76.8
to 156 minutes for IND and 95 to
144 minutes for comparators.

Analgesia
Analgesia was reported by using the
FLACC scale by Surendar et al40 in
children undergoing dental
procedures and Xie et al38 in children
undergoing IV insertion. The FLACC
scale is scored from 0 to 10, with
higher scores denoting greater pain.43
* 23,25,26,28,30,33,34,36,37,40,41
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FIGURE 3
GRADE evidence proﬁle. a We chose not to downgrade for allocation concealment (selection bias) because although most trials were judged to have an
unclear risk of bias, in all cases, this was because of insufﬁcient details provided. b Signiﬁcant heterogeneity (I2 = 72%) is partially explained by different
comparators. c Use of a nonstandardized tool to determine level and adequacy of sedation in at least 1 study limits the degree to which the results can be
applied broadly. d Use of nonstandardized tools to deﬁne the onset of sedation was prevalent across trials. e This was downgraded for consistency
because of the large range in this outcome, which was in turn likely due to heterogeneity in measurement instruments, dose, and comparators. f We were
unable to assess this given only 1 study reporting this outcome. g The total sample size was ,200 participants. h Li et al29 was judged to have high risk of
bias for incomplete outcome data because 14 of 67 participants in the IND 2 mg/kg arm withdrew post–random assignment and did not return to the
sedation center. i Surendar et al40 did not report adverse effects but reported vital signs during sedation that appeared to be within physiologic
parameters, and the risk of bias was deemed to be unclear. j Adverse effects were not deﬁned by using standardized or objective criteria. k Use of
nonstandardized tools to assess tolerability of intranasal sprays limits the degree to which the results can be applied broadly.

Using a pairwise comparison,
Surendar et al40 reported that mean
(SD) FLACC scores for 1 mg/kg of IND
(3.8 [0.8]), 1.5 mg/kg of IND (3.7
[0.9]), and 5 mg/kg of intranasal
ketamine (3.5 [0.7]) were
signiﬁcantly lower than 0.2 mg/kg of
intranasal midazolam (5.6 [1.1]) (P
value not reported). Xie et al38
reported a lower median (IQR) FLACC
score for 2 mg/kg of IND by MAD (1
[3.5]) versus nasal drops (3 [4]) (P =
.02).

Adverse Events
Adverse events were reported in all
trials except Surendar et al.40 Across
the remaining 18 trials, the most
common adverse events of IND, IND

plus another sedative, or non-IND
comparator were bradycardia (32
of 1484 [2.2%], 0 of 41 [0%], and 6
of 595 [1%], respectively),
hypotension (18 of 1484 [1.2%], 0 of
41 [0%], and 9 of 595 [1.5%],
respectively), oxygen desaturation (7
of 1484 [0.5%], 0 of 41 [0%], and 12
of 595 [2%], respectively), and
vomiting (6 of 1484 [0.4%], 3 of 41
[7.3%], and 47 of 595 [7.9%],
respectively). No trials used
objective criteria to deﬁne adverse
events. No trials reported the
occurrence of upper airway
obstruction, apnea, death, the
delivery of positive pressure
ventilation, chest compressions,
vasoactive medications, endotracheal

intubation, or neuromuscular
blockade.

Acceptance of Intranasal
Administration
The authors of 4 trials reported
acceptability of intranasal
administration. Zhang et al33 reported
all 94 participants tolerated IND
“without crying.” Xie et al38 reported
25 of 49 (51%) vs 22 of 57 (38.6%)
participants “calmly accepted” IND
using a MAD versus drops,
respectively. Patel et al41 reported
acceptance of IND was “fair to
excellent” in 16 of 22 (72.7%)
participants. Surendar et al40
reported IND and intranasal

Downloaded from www.aappublications.org/news by guest on May 10, 2021
PEDIATRICS Volume 145, number 1, January 2020

7

midazolam were “well accepted” by
all 84 participants.

Agreement Between Reviewers
Two independent reviewers (N.P.,
J.S.) agreed 102 of 114 (89.5%) times
on risk of bias assessments, 366 of
430 (85.1%) times on abstract
screening, and 74 of 79 (93.7%)
times on full-text screening.

Publication Bias
The funnel plot for adequacy of
sedation revealed some asymmetry
(Supplemental Information).

DISCUSSION
In this review, the overall quality of
evidence for adequacy of sedation
was low. Although our ﬁndings
suggest that IND likely provides
adequate sedation to a greater
proportion of children than
conventional sedatives (oral
midazolam and chloral hydrate), trial
results could not be pooled, and
larger and more methodologically
rigorous trials are needed before
widespread implementation.
Clinicians considering the use of IND
to alleviate procedural anxiety in
children must weigh the beneﬁt of
superior sedation against the
potential for adverse cardiovascular
effects, which require further
rigorous study to fully assess the risk.
We chose to include trials that used
midazolam and chloral hydrate as
comparators because they are widely
used in clinical practice.44 In fact,
chloral hydrate is recommended by
the National Institute for Health and
Care Excellence 2010 guideline for
moderate sedation for painless
procedures in children.45 Although
chloral hydrate is no longer approved
by the US Food and Drug
Administration, it may still be used in
other countries. IND provided
adequate sedation in 79.7% of
children, greater than that of chloral
hydrate (75.7%) and oral (24.1%)
and intranasal midazolam (43.4%).
This is consistent with a recent

systematic review in which IND was
superior to oral benzodiazepines in
children undergoing anesthetic
premedication,16 another systematic
review in which authors found
inconsistent evidence of procedural
anxiolysis for intranasal midazolam,11
and with a trial of 300 children
undergoing ABR testing in which IND
sedated signiﬁcantly more children
than chloral hydrate (91% vs 78.5%,
respectively).42 IND may be a safer
alternative to chloral hydrate given
the latter’s propensity to cause
respiratory depression46 and other
major adverse effects such as
bradycardia, hypotension, and oxygen
desaturation.47 In response to
evidence that general anesthetics and
sedatives in young children may have
adverse neurodevelopmental
consequences, in 2016, the US Food
and Drug Administration issued
a Drug Safety Communications
mandating label changes for all
anesthetic gases as well as the IV
agents propofol, ketamine,
barbiturates, and benzodiazepines.48
Dexmedetomidine has been shown to
be neuroprotective in animal
studies,49 but little long-term data in
humans exist. Although IND was
reported to produce adequate
sedation in more children than
intranasal ketamine (79.7% vs
57.8%), IND was deemed neutral
versus intranasal ketamine in all
trials that compared the 2
agents.35,36,40 Each trial was small
and may not have been sufﬁciently
powered to detect differences in
sedation. IND, however, may be more
suitable than intranasal ketamine for
uncooperative children because fewer
intranasal sprays are required. At
100 mg/mL, an IND dose of 4 mg/kg
in a child weighing 25 kg would only
require two 0.5 mL sprays.
Interestingly, in a single study of
children undergoing IV insertion, IND
was deemed unfavorable compared
to a combination of IND and oral
ketamine, with the latter producing
adequate sedation in 80.4% of
children.37 The sedative effects of

dexmedetomidine may have
complemented the well-known
analgesic effects of intranasal
ketamine,50,51 and future studies
should explore the sedative potential
of this novel therapeutic combination.
The most effective noninvasive
approach to providing
dexmedetomidine appeared to be the
intranasal route. Although informed
by only 1 trial, oral dexmedetomidine
was unsuccessful in all cases.41 Oral
absorption of dexmedetomidine is
possible,52 but its bioavailability is
reduced by ﬁrst-pass metabolism.53
What remains unclear is whether IND
administration using a MAD is more
efﬁcacious than nasal drops. Li et al27
found no difference among children
undergoing TTE, a relatively painless
procedure. In contrast, Xie et al38
found lower pain scores during IV
insertion using a MAD. Nasal drops
may result in excess volume entering
the oropharynx and more difﬁcult
administration in uncooperative
patients. Conversely, the MAD takes
advantage of the nasal cavity’s large
mucosal surface area and rich
vascular supply,13,54,55 resulting in
a median bioavailability of 65%.53
Insight into the analgesic potential of
IND was limited to 2 trials in which
authors reported lower FLACC scores
with IND versus intranasal
midazolam for dental procedures40
and IND using a MAD versus drops
for IV insertion.38 Reduced opioid
requirements have been reported
with IND in children
postadenotonsillectomy56 and adults
post–hip arthroplasty.57 IV
dexmedetomidine has also been
shown to reduce opioid requirements
in children undergoing scoliosis
repair58 and cardiac surgery.59
However, the proportion of
participants deemed as being
adequately sedated for painful versus
nonpainful procedures (61.2% vs
84.1%) suggests that sedation using
IND may be improved by the addition
of a more potent analgesic, perhaps
one with sedative properties.
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Currently, IND as monotherapy is not
indicated for severely painful
procedures, and its analgesic
potential appears to be realized in
conjunction with local anesthetics.60
Future studies should explore the
analgesic potential of IND for acutely
painful procedures using rigorous
methodology and optimal dosing.
The onset and duration of sedation are
important considerations in a busy
acute care setting. We found wide
ranges in onset and duration of IND
(7–31 and 41–91.5 minutes,
respectively), and data did not support
a dose effect. This may reﬂect
heterogeneity in dosing or deﬁnitions
of sedation but are consistent with
previous reports. Among healthy adult
men, Iirola et al53 reported a median
(range) peak plasma concentration at
38 (15–60) minutes and onset of
sedation of 30 to 45 minutes. In
children, Yuen et al61 reported
a median (95% conﬁdence interval
[CI]) onset and duration of sedation of
25 (25–30) and 85 (55–100) minutes,
respectively. These results suggest that
IND should be administered at least
30 minutes before an anxietyprovoking procedure.53 The American
Academy of Pediatrics has published
guidelines outlining monitoring
requirements for children undergoing
procedural sedation. Regardless of
agent or route of administration, all
children should receive comprehensive
monitoring for the duration of sedation.
This should include, but is not limited
to, pulse oximetry and capnography.62
Acceptance of intranasal administration
was only assessed in 4 trials and not
objectively. However, there is good
reason to believe that intolerance of
nasal sprays is unlikely to preclude IND
administration because the drug is
tasteless, odorless, and painless53,54
and reportedly “not noxious to the
nasal mucosa,”53,63 a notable difference
from intranasal midazolam in which
discomfort is commonly reported.12,13
Adverse effects identiﬁed in our
review such as bradycardia,

hypotension, and desaturation were
reported across the dosing range and
are likely to inform bedside
monitoring requirements. For the
adverse cardiovascular effects we
identiﬁed, no resuscitative maneuvers
were reported, suggesting they were
self-resolving. This is consistent with
2 pediatric systematic reviews in
which authors reported no respiratory
compromise with either IND16 or IV
dexmedetomidine.15 In addition,
authors of several pediatric studies
found that IV dexmedetomidine was
associated with bradycardia without
hemodynamic instability.15,54,58,64,65
Nevertheless, it is difﬁcult to know to
what degree these occurrences
compromised patient care. The most
prudent approach would be to limit the
use of IND to children without cardiac
conduction anomalies, bradycardia,
hypotension, or concomitant use of
sympatholytic agents. Future studies
should be used to deﬁne adverse events
and corresponding interventions on the
basis of published guidelines.66
Our review included a large number
of small studies with some
methodologic shortcomings, the most
notable of which was subjective
determination of adequacy of
sedation. The lack of a consistent and
objective determination of this
parameter may have led to biased
outcome reporting for this and other
related outcomes such as onset and
duration of sedation. Because of
heterogeneity in dosing and
indications, it was difﬁcult to
appreciate differences in adequate
sedation among trials that used
validated sedation instruments
versus trials that did not. However, on
the basis of the classiﬁcation system
outlined by the American College of
Emergency Physicians’ clinical policy,
we believe that across trials, adequate
sedation most closely paralleled
dissociative sedation, with the caveat
that few trials determined the degree of
analgesia and no trials assessed
amnesia.67 We found large
heterogeneity across studies, which may

be because of different comparators.
The funnel plot revealed some
asymmetry, suggesting the potential for
publication or small study bias. As such,
we downgraded our certainty of the
evidence for some outcomes.

CONCLUSIONS
Our ﬁndings suggest that IND is well
tolerated and may provide more
effective sedation than midazolam and
chloral hydrate for distressing
procedures in children. However, the
quality of evidence was low, and larger,
more methodologically rigorous trials
are needed. The available limited data
for painful procedures (mostly IV
insertion) suggest that although IND
may provide reasonable sedation, it
may not provide adequate analgesia as
monotherapy. As such, more study is
urgently required to understand the
role of IND, perhaps in combination
with a more widely studied analgesic
sedative for painful procedures.
Transient cardiovascular adverse
effects, without reports of resuscitative
intervention, were identiﬁed, and more
rigorously designed trials with
standardized and objective reporting of
adverse effects are needed to inform
the safe use of IND in children.

ABBREVIATIONS
ABR: auditory brainstem response
CI: conﬁdence interval
CT: computed tomography
FLACC: Faces, Legs, Activity, Cry,
and Consolability
GRADE: Grading of
Recommendations
Assessment,
Development, and
Evaluation
IND: intranasal dexmedetomidine
IQR: interquartile range
IV: intravenous
MAD: mucosal atomizer device
TTE: transthoracic
echocardiography
VEP: visually evoked potential
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